Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
Open Access
- 23 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and/or recruit different immune populations. T-cell enabling virotherapy could enhance the efficacy of immune checkpoint inhibitors, even in tumors resistant to these inhibitors. The T-cell potentiating virotherapy used here consisted of adenoviruses engineered to express tumor necrosis factor alpha and interleukin-2 in the tumor microenvironment. To study virus efficacy in checkpoint-inhibitor resistant tumors, we developed an anti-PD-1 resistant melanoma model in vivo. In resistant tumors, adding virotherapy to an anti-PD-1 regimen resulted in increased survival (p=0.0009), when compared to anti-PD-1 monotherapy. Some of the animals receiving virotherapy displayed complete responses, which did not occur in the immune checkpoint-inhibitor monotherapy group. When adenoviruses were delivered into resistant tumors, there were signs of increased CD8 T-cell infiltration and activation, which - together with a reduced presence of M2 macrophages and myeloid-derived suppressor cells - could explain those results. T-cell enabling virotherapy appeared as a valuable tool to counter resistance to immune checkpoint inhibitors. The clinical translation of this approach could increase the number of cancer patients benefiting from immunotherapies.Funding Information
- Orionin Tutkimussäätiö
- Jane ja Aatos Erkon Säätiö
- Helsingin ja Uudenmaan Sairaanhoitopiiri
- Sigrid Juséliuksen Säätiö
- Finnish Cancer Institute
- Helsingin Yliopisto
- Novo Nordisk Fonden
- Päivikki ja Sakari Sohlbergin Säätiö
- Suomen Tiedeseura
- Horizon 2020
This publication has 53 references indexed in Scilit:
- The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A reviewEuropean Journal of Cancer, 2019
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?Asco Educational Book, 2019
- Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic ReviewCancers, 2019
- A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerFrontiers in Oncology, 2019
- Cancer immunologists scoop medicine Nobel prizeNature, 2018
- Complex pattern of immune evasion in MSI colorectal cancerOncoImmunology, 2018
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaImmunity, 2017
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsCancer Discovery, 2017
- New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a BackboneThe Cancer Journal, 2017